Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Update

Sol-Gel Technologies Ltd. (NASDAQ:SLGLGet Free Report) was the recipient of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 17,300 shares, a growth of 82.1% from the January 31st total of 9,500 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 26,900 shares, the days-to-cover ratio is presently 0.6 days.

Sol-Gel Technologies Stock Down 4.1 %

Sol-Gel Technologies stock traded down $0.05 during trading hours on Thursday, hitting $1.13. 9,112 shares of the company traded hands, compared to its average volume of 26,627. The firm has a market cap of $26.18 million, a P/E ratio of -1.08 and a beta of 1.42. The firm’s 50-day simple moving average is $1.20 and its two-hundred day simple moving average is $1.57. Sol-Gel Technologies has a 1-year low of $0.90 and a 1-year high of $4.66.

Hedge Funds Weigh In On Sol-Gel Technologies

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its position in shares of Sol-Gel Technologies by 349.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,643 shares of the company’s stock valued at $28,000 after purchasing an additional 4,387 shares in the last quarter. Raymond James & Associates boosted its holdings in shares of Sol-Gel Technologies by 25.4% in the first quarter. Raymond James & Associates now owns 47,492 shares of the company’s stock worth $350,000 after buying an additional 9,631 shares during the period. Yelin Lapidot Holdings Management Ltd. acquired a new stake in shares of Sol-Gel Technologies during the third quarter worth approximately $374,000. Finally, Armistice Capital LLC acquired a new stake in shares of Sol-Gel Technologies during the first quarter worth approximately $9,343,000. Institutional investors own 34.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright dropped their price objective on shares of Sol-Gel Technologies from $12.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 13th.

Check Out Our Latest Analysis on Sol-Gel Technologies

About Sol-Gel Technologies

(Get Free Report)

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications.

See Also

Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with's FREE daily email newsletter.